|Bid||36.85 x 800|
|Ask||36.90 x 1200|
|Day's Range||36.55 - 37.05|
|52 Week Range||26.95 - 50.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||43.82|
Short interest is low for PCRX with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 13. Over the last one-month, outflows of investor capital in ETFs holding PCRX totaled $1.40 billion.
Pacira (PCRX) announces robust preliminary results for Exparel sales in second quarter on the back of increasing adoption for pain management in surgical procedures.
Pacira Pharmaceuticals, Inc. (PCRX) today reported preliminary EXPAREL® (bupivacaine liposome injectable suspension) net product sales of $80.4 million for the second quarter of 2018, a 15 percent increase over EXPAREL net product sales of $69.8 million reported in the second quarter of 2017. “We are excited to report another consecutive quarter of accelerating sales growth, representing the expanding adoption of EXPAREL as an integral component of multimodal, non-opioid pain management strategies in a variety of surgical procedures,” said Dave Stack, chairman and chief executive officer of Pacira. “Our Johnson & Johnson partnership is flourishing and we are continuing to see a high level of engagement and enthusiasm around the launch of EXPAREL as the first long-acting, single-dose nerve block for upper extremity surgeries with increasing demand from new and existing accounts.
Short interest is moderate for PCRX with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 8. The net inflows of $2.85 billion over the last one-month into ETFs that hold PCRX are not among the highest of the last year and have been slowing.
Ahead of today's trading session, WallStEquities.com assesses Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), SCYNEXIS Inc. (NASDAQ: SCYX), and The Medicines Co. (NASDAQ: MDCO). The biggest catalyst of the Generic Drugs industry is the significantly lower price of generics compared to branded drugs.
In this article I am going to calculate the intrinsic value of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by estimating the company’s future cash flows and discounting them to their present value.Read More...
Heron Therapeutics Inc. shares surged 30% Thursday, after the company announced positive developments for its treatment for postoperative pain that aims to reduce patient dependence on opioids. It then said that its HTX-011, which was the focus of the two studies, has won breakthrough therapy designation from the U.S. Food and Drug Administration. HTX-011 is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam and is intended for the management of postoperative pain.
Pacira Pharmaceuticals, Inc. (PCRX) and Nuance Biotech Co. Ltd (Nuance) today announced that they have entered into an agreement with Nuance, a China based specialty pharmaceutical company, to advance the development and commercialization of EXPAREL® (bupivacaine liposome injectable suspension) in China. EXPAREL is a non-opioid option for achieving long-lasting pain control after surgery via infiltration into the surgical site or administration as an interscalene brachial plexus nerve block.
NEW YORK, June 18, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Microchip ...
Pacira Pharmaceuticals, Inc. today announced further collaboration with Aetna, one of the nation’s leading diversified health care benefits companies. Aetna has updated its online provider directory, DocFind, to help members easily identify surgeons who are committed to offering opioid alternatives, including EXPAREL® (bupivacaine liposome injectable suspension), to manage postsurgical pain. This initiative builds off a national program launched by Pacira, Aetna, and the American Association of Oral and Maxillofacial Surgeons (AAOMS) in September 2017 aimed at reducing the number of opioid tablets prescribed to Aetna patients undergoing impacted wisdom tooth extractions through the use of EXPAREL.
MEDNAX, Inc. (MD), the national health solutions partner specializing in anesthesiology, neonatology, maternal-fetal medicine, other pediatric services, radiology and management services, is pleased to announce that it has partnered with Pacira Pharmaceuticals, Inc. (PCRX) to address the ongoing use of opioids during and after cesarean surgery by launching a national collaborative aimed at addressing the Quadruple Aim through the implementation of an Enhanced Recovery after Cesarean Surgery (ERACS™) program. The collaborative will be multi-disciplinary in nature, engaging the expertise of maternal-fetal medicine physicians, anesthesiologists, obstetricians and perioperative nurses to improve the patient experience as well as maternal and infant health, reduce the total cost of care and enhance provider satisfaction.
Pacira Pharmaceuticals (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PARSIPPANY, N.J., May 31, 2018-- Pacira Pharmaceuticals, Inc. today reported that Dave Stack, chairman and chief executive officer, will present at the Jefferies 2018 Healthcare Conference at 9:30 AM ET ...
Pre-market, WallStEquities.com takes a look at the recent performance of Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), SCYNEXIS Inc. (NASDAQ: SCYX), and The Medicines Co. (NASDAQ: MDCO). On Wednesday, shares in Canonsburg, Pennsylvania headquartered Mylan N.V. recorded a trading volume of 3.81 million shares.
On a per-share basis, the Parsippany, New Jersey-based company said it had a loss of 26 cents. Earnings, adjusted for stock option expense and amortization costs, were 2 cents per share. The results did ...
--EXPAREL ® net product sales of $74.0 million up 9% over prior year first quarter---- Conference call today at 8:30 a.m. ET--. PARSIPPANY, N.J., May 03, 2018-- Pacira Pharmaceuticals, Inc. today announced ...
Pacira Pharmaceuticals, Inc. (PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012.
PARSIPPANY, N.J., April 26, 2018-- Pacira Pharmaceuticals, Inc. today announced that it will report its first quarter financial results before the open of the U.S. markets on Thursday, May 3, 2018. The ...
NEW YORK, April 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program.
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is drawing a considerable amount of attention in the biotechnology space as we start a fresh week of trading, with the activity rooted in an event that hit press shortly before markets closed out for the session last Friday. Here is what happened. For anybody not familiar with Pacira, this one […] The post Here’s Why The Latest News Is A Big Deal For Pacira Pharmaceuticals appeared first on Market Exclusive.